HA-based vaccines provide limited cross-protection against novel influenza virus.
The M2e-based vaccine is considered universal candidate against influenza virus.
M2e5x VLPs induce M2e-specific antibodies, but not provide protection.
Supplementation with M2e5x VLPs provide good protection against HPAI H5 viruses.